BACKGROUND: Spontaneous control of human immunodeficiency virus (HIV) infection has been documented in a minority of HIV-infected individuals. The mechanisms behind this outcome remain largely unknown, and a better understanding of them will likely influence future vaccine strategies. METHODS: HIV-specific T cell and antibody responses as well as host genetics were examined in untreated HIV-infected patients who maintain comparatively low plasma HIV RNA levels (hereafter, controllers), including those with levels of < 50 RNA copies/mL (elite controllers, n = 64), those with levels of 50-2000 copies/mL (viremic controllers, n = 60); we also examined HIV-specific T cell and antibody responses as well as host genetics for patients with levels of >10,000 copies/mL (chronic progressors, n = 30). RESULTS: CD8+ T cells from both controller groups preferentially target Gag over other proteins in the context of diverse HLA class I alleles, whereas responses are more broadly distributed in persons with progressive infection. Elite controllers represent a distinct group of individuals who have significantly more CD4 and CD8 T cells that secrete interferon-gamma and interleukin-2 and lower levels of HIV-neutralizing antibodies. Individual responses were quite heterogeneous, and none of the parameters evaluated was uniquely associated with the ability to control viremia. CONCLUSIONS: Elite controllers are a distinct group, even when compared to persons with low level viremia, but they exhibit marked genetic and immunologic heterogeneity. Even low-level viremia among HIV controllers was associated with measurable T cell dysfunction, which has implications for current prophylactic vaccine strategies.
BACKGROUND: Spontaneous control of human immunodeficiency virus (HIV) infection has been documented in a minority of HIV-infected individuals. The mechanisms behind this outcome remain largely unknown, and a better understanding of them will likely influence future vaccine strategies. METHODS:HIV-specific T cell and antibody responses as well as host genetics were examined in untreated HIV-infectedpatients who maintain comparatively low plasma HIV RNA levels (hereafter, controllers), including those with levels of < 50 RNA copies/mL (elite controllers, n = 64), those with levels of 50-2000 copies/mL (viremic controllers, n = 60); we also examined HIV-specific T cell and antibody responses as well as host genetics for patients with levels of >10,000 copies/mL (chronic progressors, n = 30). RESULTS:CD8+ T cells from both controller groups preferentially target Gag over other proteins in the context of diverse HLA class I alleles, whereas responses are more broadly distributed in persons with progressive infection. Elite controllers represent a distinct group of individuals who have significantly more CD4 and CD8 T cells that secrete interferon-gamma and interleukin-2 and lower levels of HIV-neutralizing antibodies. Individual responses were quite heterogeneous, and none of the parameters evaluated was uniquely associated with the ability to control viremia. CONCLUSIONS: Elite controllers are a distinct group, even when compared to persons with low level viremia, but they exhibit marked genetic and immunologic heterogeneity. Even low-level viremia among HIV controllers was associated with measurable T cell dysfunction, which has implications for current prophylactic vaccine strategies.
Authors: Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin Journal: J Virol Date: 2010-10-06 Impact factor: 5.103
Authors: Yanhua Tang; Sihong Huang; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; Elizabeth G Ryland; M Anne St John; Rohan Hazra; Celia D C Christie; Margaret E Feeney Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Mathieu Angin; Hendrik Streeck; Fang Wen; Melanie King; Florencia Pereyra; Marcus Altfeld; Bruce D Walker; Marylyn M Addo Journal: AIDS Res Hum Retroviruses Date: 2012-04-05 Impact factor: 2.205
Authors: Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker Journal: J Virol Date: 2011-12-07 Impact factor: 5.103
Authors: Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles Journal: Blood Date: 2012-04-05 Impact factor: 22.113
Authors: Brenda De Keersmaecker; Sabine D Allard; Patrick Lacor; Rik Schots; Kris Thielemans; Joeri L Aerts Journal: J Virol Date: 2012-06-20 Impact factor: 5.103
Authors: April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett Journal: J Virol Date: 2010-08-18 Impact factor: 5.103
Authors: María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal Journal: J Virol Date: 2018-02-12 Impact factor: 5.103
Authors: Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon Journal: AIDS Date: 2012-11-28 Impact factor: 4.177